Breast Cancer Female, Osteoporosis
Conditions
Keywords
Aromatase Inhibitors, Bone pathology, QoL
Brief summary
Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
Interventions
BEHAVIORALObservational Analysis
Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients willing to provide the Informed consent to participate to the study * Women aged 18-75 years * Patients having breast cancer, with no phenotype restrictions * Patients in natural and stable menopause * Patients having secondary amenorrhea, that arose after the initiation of oncologic treatment, since at least 12 months or 6 months with FSH\> 40 U/I
Exclusion criteria
* Patients with advanced cancer and/or bone metastases and/or visceral metastases * Patients with severe renal insufficiency and/or in dialysis and patients affected by severe endocrine disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Results from some questionnaires related to patients QoL, rated from 1 to 10. | 26-32 months | Description of the current state of the most frequent clinical and therapeutical approaches to bone diseases in 700 breast cancer menopausal patients treated with adjuvant and/or hormonal therapy. These patients are assessed by questionnaires regarding quality of life, menopausal status and current anti resorptive treatments |
Countries
Italy
Contacts
Primary ContactPaola Villa, Md PhD
Outcome results
None listed